Project 1: Biomarkers for Characterizing and Predicting AD in DS

项目 1:用于表征和预测 DS 中 AD 的生物标志物

基本信息

  • 批准号:
    10454259
  • 负责人:
  • 金额:
    $ 61.35万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-30 至 2025-08-31
  • 项目状态:
    未结题

项目摘要

Project 1 Abstract An overarching theme of the Alzheimer's Disease Biomarkers-Down syndrome (ABC-DS) program is to characterize Alzheimer disease (AD) in Down syndrome (DS) and to determine if it has a pathological progression comparable to late onset AD (LOAD) and thus can inform translational research focused on prevention and treatment for all people with AD. People with DS are at extremely high risk of AD in middle age due, at least in large measure, to lifelong overexpression of the gene coding for APP, located on Chr. 21. A hypothesized model has been proposed for LOAD consisting of early amyloid (A) deposition followed by tau (T) deposition and then neurodegeneration (N) (AT(N)). Inflammation and cerebrovascular disease (CVD) are more common in adults with DS and may modify the AT(N) framework. Project 1 utilizes outcomes collected by ABC- DS Cores to follow the conversion of adults with DS from when they are clinically unaffected by AD to progression of incident MCI-DS and subsequent dementia. This project will determine if the AT(N) framework is descriptive of AD progression in adults with DS and, if different, in what way. A second priority is to determine if AD risk and progression is modified by certain risk factors. Aim 1 examines the AT(N) framework with regard to the development of symptomatic cognitive decline (MCI-DS/Dementia). We hypothesize that early changes in amyloid (A) are followed by changes in neurofibrillary pathology (T) and then changes in neurodegeneration (N). We predict the overall sequence of events that leads to symptomatic cognitive decline in DS is similar to AD in other at risk AD populations but quantitative differences will be present in the time span over which these events occur. Aim 2 examines the contribution of selected factors that modify the risk or progression to cognitive decline (MCI-DS/dementia) and in the AT(N) framework to lead to individual variability in DS. We hypothesize that inflammatory changes and cerebrovascular disease (CVD) modify the risk of amyloid and tau deposition. Furthermore, we hypothesize that sex and commonly co-occurring medical conditions (e.g. seizures, hyperlipidemia, obesity, and sleep apnea) may contribute to the heterogeneity in the age at onset of MCI-DS and/or the rate of progression from MCI-DS to dementia. Aim 3 examines select factors that contribute to within- population variability in AD vulnerability in collaboration with Projects 2 and 3. Results from this Project could contribute to efforts to discover effective intervention(s) within this high risk population and for AD more broadly.
项目1 阿尔茨海默病生物标志物-唐氏综合征(ABC-DS)计划的首要主题是 描述唐氏综合征(DS)中的阿尔茨海默病(AD),并确定其是否具有病理性 与晚发性AD(LOAD)相当的进展,因此可以为专注于以下方面的转化研究提供信息 为所有AD患者提供预防和治疗。DS患者在中年时患AD的风险极高 至少在很大程度上是由于位于Chr. 21上的APP编码基因的终生过表达。一 已经提出了LOAD的假设模型,其由早期淀粉样蛋白(A)沉积和随后的tau(T)组成, 沉积,然后是神经变性(N)(AT(N))。炎症和脑血管疾病(CVD) 常见于DS成人,可能改变AT(N)框架。项目1利用ABC收集的结果- DS核心追踪DS成人从临床上不受AD影响到进展的转变 突发性MCI-DS和随后的痴呆症本项目将确定AT(N)框架是否是描述性的 AD在DS成人中的进展,如果不同,以何种方式。第二个优先事项是确定AD风险和 某些风险因素会影响进展。目标1审查了AT(N)框架, 出现症状性认知功能减退(MCI-DS/痴呆)。我们假设, 淀粉样蛋白(A)之后是神经病理学变化(T),然后是神经变性变化(N)。 我们预测导致DS症状性认知功能下降的事件的总体顺序与AD相似, 其他有风险的AD人群,但这些事件发生的时间跨度将存在数量差异 发生.目标2检查了所选因素对认知能力下降风险或进展的影响 (MCI-DS/痴呆)和AT(N)框架导致DS的个体差异。我们假设 炎症变化和脑血管疾病(CVD)改变了淀粉样蛋白和tau沉积的风险。 此外,我们假设,性别和常见的共同发生的医疗条件(如癫痫发作, 高脂血症、肥胖和睡眠呼吸暂停)可能导致MCI-DS发病年龄的异质性 和/或从MCI-DS进展为痴呆的速率。目标3审查有助于内部- 与项目2和项目3合作,研究AD脆弱性的人口变异性。该项目的成果可以 有助于在这一高风险人群中以及更广泛地为AD发现有效的干预措施。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Beau M Ances其他文献

Prediction of amyloid and tau brain deposition and cognitive decline in people with Down syndrome using plasma biomarkers: a longitudinal cohort study
利用血浆生物标志物预测唐氏综合征患者的淀粉样蛋白和tau 蛋白脑沉积及认知能力下降:一项纵向队列研究
  • DOI:
    10.1016/s1474-4422(25)00158-9
  • 发表时间:
    2025-07-01
  • 期刊:
  • 影响因子:
    45.500
  • 作者:
    Shorena Janelidze;Lyduine E Collij;Niklas Mattsson-Carlgren;Alex Antill;Charles M Laymon;Ira Lott;H Diana Rosas;Davneet S Minhas;Weiquan Luo;Shahid Zaman;Alzheimer's Biomarker Consortium–Down Syndrome investigators;Mark Mapstone;Elizabeth Head;Florence Lai;Sigan L Hartley;Beau M Ances;Sharon J Krinsky-McHale;Joseph H Lee;Rik Ossenkoppele;Bradley T Christian;Benjamin L Handen;Oskar Hansson
  • 通讯作者:
    Oskar Hansson
Timeline to symptomatic Alzheimer's disease in people with Down syndrome as assessed by amyloid-PET and tau-PET: a longitudinal cohort study
唐氏综合征患者症状性阿尔茨海默病的时间线(通过淀粉样蛋白-PET 和 tau-PET 评估):一项纵向队列研究
  • DOI:
    10.1016/s1474-4422(24)00426-5
  • 发表时间:
    2024-12-01
  • 期刊:
  • 影响因子:
    45.500
  • 作者:
    Emily K Schworer;Matthew D Zammit;Jiebiao Wang;Benjamin L Handen;Tobey Betthauser;Charles M Laymon;Dana L Tudorascu;Annie D Cohen;Shahid H Zaman;Beau M Ances;Mark Mapstone;Elizabeth Head;Bradley T Christian;Sigan L Hartley;Howard Aizenstein;Beau Ances;Howard Andrews;Karen Bell;Rasmus Birn;Adam Brickman;Fan Zhang
  • 通讯作者:
    Fan Zhang
Technology Insight: can neuroimaging provide insights into the role of ischemia in Baló's concentric sclerosis?
技术洞察:神经影像学能否为缺血在巴尔通体同心性硬化中的作用提供见解?
  • DOI:
    10.1038/ncpneuro0519
  • 发表时间:
    2007-06-01
  • 期刊:
  • 影响因子:
    33.100
  • 作者:
    Ellen M Mowry;John H Woo;Beau M Ances
  • 通讯作者:
    Beau M Ances

Beau M Ances的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Beau M Ances', 18)}}的其他基金

HABS-HD - Project 1
HABS-HD - 项目 1
  • 批准号:
    10493852
  • 财政年份:
    2022
  • 资助金额:
    $ 61.35万
  • 项目类别:
Cannabis, HIV and Mental Processing Systems (CHAMPS)
大麻、艾滋病毒和心理处理系统 (CHAMPS)
  • 批准号:
    10458095
  • 财政年份:
    2021
  • 资助金额:
    $ 61.35万
  • 项目类别:
VULNERABILITY AND RESILIENCY IN THE AGING ADULT BRAIN CONNECTOME (AABC)
衰老成人大脑连接体 (AABC) 的脆弱性和弹性
  • 批准号:
    10283063
  • 财政年份:
    2021
  • 资助金额:
    $ 61.35万
  • 项目类别:
Cannabis, HIV and Mental Processing Systems (CHAMPS)
大麻、艾滋病毒和心理处理系统 (CHAMPS)
  • 批准号:
    10625336
  • 财政年份:
    2021
  • 资助金额:
    $ 61.35万
  • 项目类别:
THE ADMINISTRATION CORE (AC)
管理核心 (AC)
  • 批准号:
    10283064
  • 财政年份:
    2021
  • 资助金额:
    $ 61.35万
  • 项目类别:
THE ADMINISTRATION CORE (AC)
管理核心 (AC)
  • 批准号:
    10673892
  • 财政年份:
    2021
  • 资助金额:
    $ 61.35万
  • 项目类别:
Cannabis, HIV and Mental Processing Systems (CHAMPS)
大麻、艾滋病毒和心理处理系统 (CHAMPS)
  • 批准号:
    10261977
  • 财政年份:
    2021
  • 资助金额:
    $ 61.35万
  • 项目类别:
VULNERABILITY AND RESILIENCY IN THE AGING ADULT BRAIN CONNECTOME (AABC)
衰老成人大脑连接体 (AABC) 的脆弱性和弹性
  • 批准号:
    10673890
  • 财政年份:
    2021
  • 资助金额:
    $ 61.35万
  • 项目类别:
Project 1: Biomarkers for Characterizing and Predicting AD in DS
项目 1:用于表征和预测 DS 中 AD 的生物标志物
  • 批准号:
    10264842
  • 财政年份:
    2020
  • 资助金额:
    $ 61.35万
  • 项目类别:
Project 1: Biomarkers for Characterizing and Predicting AD in DS
项目 1:用于表征和预测 DS 中 AD 的生物标志物
  • 批准号:
    10667598
  • 财政年份:
    2020
  • 资助金额:
    $ 61.35万
  • 项目类别:

相似海外基金

Hormone therapy, age of menopause, previous parity, and APOE genotype affect cognition in aging humans.
激素治疗、绝经年龄、既往产次和 APOE 基因型会影响老年人的认知。
  • 批准号:
    495182
  • 财政年份:
    2023
  • 资助金额:
    $ 61.35万
  • 项目类别:
Investigating how alternative splicing processes affect cartilage biology from development to old age
研究选择性剪接过程如何影响从发育到老年的软骨生物学
  • 批准号:
    2601817
  • 财政年份:
    2021
  • 资助金额:
    $ 61.35万
  • 项目类别:
    Studentship
RAPID: Coronavirus Risk Communication: How Age and Communication Format Affect Risk Perception and Behaviors
RAPID:冠状病毒风险沟通:年龄和沟通方式如何影响风险认知和行为
  • 批准号:
    2029039
  • 财政年份:
    2020
  • 资助金额:
    $ 61.35万
  • 项目类别:
    Standard Grant
Neighborhood and Parent Variables Affect Low-Income Preschool Age Child Physical Activity
社区和家长变量影响低收入学龄前儿童的身体活动
  • 批准号:
    9888417
  • 财政年份:
    2019
  • 资助金额:
    $ 61.35万
  • 项目类别:
The affect of Age related hearing loss for cognitive function
年龄相关性听力损失对认知功能的影响
  • 批准号:
    17K11318
  • 财政年份:
    2017
  • 资助金额:
    $ 61.35万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    9320090
  • 财政年份:
    2017
  • 资助金额:
    $ 61.35万
  • 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    10166936
  • 财政年份:
    2017
  • 资助金额:
    $ 61.35万
  • 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    9761593
  • 财政年份:
    2017
  • 资助金额:
    $ 61.35万
  • 项目类别:
How age dependent molecular changes in T follicular helper cells affect their function
滤泡辅助 T 细胞的年龄依赖性分子变化如何影响其功能
  • 批准号:
    BB/M50306X/1
  • 财政年份:
    2014
  • 资助金额:
    $ 61.35万
  • 项目类别:
    Training Grant
Inflamm-aging: What do we know about the effect of inflammation on HIV treatment and disease as we age, and how does this affect our search for a Cure?
炎症衰老:随着年龄的增长,我们对炎症对艾滋病毒治疗和疾病的影响了解多少?这对我们寻找治愈方法有何影响?
  • 批准号:
    288272
  • 财政年份:
    2013
  • 资助金额:
    $ 61.35万
  • 项目类别:
    Miscellaneous Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了